Table 1.
Demographic Comparison of Cannabinoid Hyperemesis Syndrome Patients and Controls
| CHS patients | Control subjects | |
|---|---|---|
| Age | Mean: 33.8 SD: 12 | Mean: 43.8 SD: 13.8 |
| Sex | Female: 53.6% Male: 46.4% | Female: 60% Male: 40% |
| Smoking habit | 85.7% daily consumers | 70% daily consumers |
| Prescribed SSRI | 10.7% | 20% |
| Prescribed PPI | 28.6% | 0% |
| Diagnosed w/CVS | 38.3% | 0% a |
| Diagnosed w/IBD | 28.6% | 0% |
| Diagnosed w/gallbladder disease/removal | 32.1% | 0% |
| Symptomatic abdominal pain | 89.3% | 0% |
| Symptomatic nausea/vomiting | 82.1% | 0% |
| Related hospitalization | 75% | 0% |
a
Control screening criteria removed any subjects with bolded conditions or symptoms.
CHS, cannabinoid hyperemesis syndrome; CVS, cyclic vomiting syndrome; IBD, inflammatory bowel disease; PPI, proton pump inhibitor; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor.